Transcript of the Earning Call held on Friday, 22 May 2026 with respect to the Audited (Standalone and Consolidated) Financial results of the Company for the quarter and year ended March 31, 2026.
RESULTS
▲ Positive Development
LOW RISK
📅 Filed on BSE: 27 May 2026, 04:23 PM IST · BSE ID: f50450ce-cdc7-41a5-8329-83732c864d9e
View Original BSE Filing (PDF)
💡
In Simple Terms
The company published details from its recent investor call discussing its strong financial results for the last quarter and full year.
🤖 AI Summary
- Suraksha Diagnostic released the earnings call transcript for Q4 and FY26 financial results.
- Q4 FY26 total revenue stood at INR822 million, marking a 25% year-on-year growth.
- Full year FY26 total revenue was INR3136 million, achieving 22.5% year-on-year growth.
- FY26 Profit After Tax (PAT) reached INR314 million, a 1.4% year-on-year growth.
- The company served 1.37 million patients and conducted 8.16 million tests in FY26.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Q4 FY26 Total Revenue
INR822 million
25%
Q4 FY25 Total Revenue
INR659 million
Q4 FY26 EBITDA
INR252 million
26%
Q4 FY25 EBITDA
INR200 million
Q4 FY26 PAT
INR62 million
Q4 FY25 PAT
INR22 million
FY26 Total Revenue
INR3136 million
22.5%
FY25 Total Revenue
INR2559 million
FY26 EBITDA
INR986 million
15.8%
FY25 EBITDA
INR851 million
FY26 PAT
INR314 million
1.4%
FY26 Patients Served
1.37 million
FY26 Tests Performed
8.16 million
FY26 Revenue Per Patient
INR2,264
🏢 How This Affects the Company
The company expanded its network, adding two hub centers, 11 spoke centers, and three PPP model centers in FY26, increasing its total count to 68 centers. It is expanding into Bihar, Tripura, and Jharkhand in FY27.
FY26 revenue from operations increased to INR3104.1 million, a 23.1% YoY growth. Blended EBITDA margin for FY26 was 31.73%, generating INR985 million EBITDA, while mature centers maintain 36% to 37% EBITDA margins.
New technology implementations include the fastest NGS platform Genexus, Roche automation in pathology labs, and 1.5T helium-free MRI technology at Calcutta Medical College. The company plans to establish three new hubs and eight spoke centers in West Bengal, plus one hub each in Bihar, Tripura, and Jharkhand in FY27.
👥 What This Means For Shareholders
✅
Action Required
No action required from shareholders based on this filing.
👤
Who Is Affected
Shareholders are provided with the detailed financial and operational performance data for Q4 and FY26, including revenue, EBITDA, and PAT figures.
🔍
Management Signal
Management is signaling a focus on continued network expansion into Eastern and Northeastern India, specialized diagnostic capabilities, and operational efficiencies.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q1 FY27 results — monitor expansion into new states like Bihar, Tripura, Jharkhand.
Updates on new hub and spoke center launches in West Bengal and adjacent geographies.
Progress reports on genomics and advanced radiology capabilities development.
LOW RISK
The filing reports positive financial results and strategic expansion plans without immediately evident new risks.
💡 Investor Takeaway
Suraksha Diagnostic reported Q4 FY26 total revenue of INR822 million, up 25% YoY, and FY26 total revenue of INR3136 million, up 22.5% YoY. FY26 PAT increased 1.4% to INR314 million. The company served 1.37 million patients and expanded its network to 68 centers.
⚖️ Strengths & Concerns
✅ Positives
- FY26 revenue from operations reached INR3104.1 million, reflecting a robust 23.1% year-on-year growth.
- Mature centers consistently delivered high EBITDA margins in the range of 36% to 37%, indicating strong operational leverage.
⚠️ Concerns
- Q4 FY26 PAT margin declined to 7.6% from 11% in Q4 FY25, primarily due to higher depreciation and finance costs.
- FY26 PAT growth was 1.4% at INR314 million compared to INR310 million in FY25, while revenue grew 22.5%.
❓ Frequently Asked Questions
What was Suraksha Diagnostic's total revenue for Q4 FY26?
Suraksha Diagnostic reported a total revenue of INR822 million for Q4 FY26, representing a year-on-year growth of 25%.
What was Suraksha Diagnostic's Profit After Tax (PAT) for the full year FY26?
The Profit After Tax (PAT) for Suraksha Diagnostic for the full year FY26 stood at INR314 million, showing a year-on-year growth of 1.4%.
How many patients did Suraksha Diagnostic serve in FY26?
Suraksha Diagnostic served 1.37 million patients across its network during FY26, performing 8.16 million clinical tests.
What was Suraksha Diagnostic's blended EBITDA margin for FY26?
The blended EBITDA margin for Suraksha Diagnostic for FY26 was 31.73%, yielding an estimated total EBITDA of INR985 million.
How many new centers did Suraksha Diagnostic launch in FY26?
In FY26, Suraksha Diagnostic launched two hub centers, 11 spoke centers, and three centers under the PPP model, increasing its total center count to 68 as of March 2026.
Questions based on this BSE filing only. For information purposes.